Атипичные раны (обзор литературы)

В статье представлен обзор литературы, посвященный проблеме диагностики и лечения атипичных ран. Обсуждаются вопросы важности хирургической настороженности при отсутствии ответа на стандартное лечение в течение 4 и более нед, необходимости тканевой биопсии и мультидисциплинарного подхода при подозрении на атипичный характер этиологии и патогенеза длительно незаживающих ран.

1. Situm M., Kolić M., Redzepi G., Antolić S. Chronic wounds as a public health problem. Acta Med Croatica. 2014; 68 (Suppl 1): 5–7.

2. Sen C. K. Human wound and its burden: updated 2020 compendium of estimates. Adv Wound Care. 2021; 10(5): 281–292.

3. Körber A., Klode J., Al‐Benna S., et al. Etiology of chronic leg ulcers in 31,619 pa- tients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges. 2011; 9 (2): 116– 121.

4. Nickles M. A., Tsoukas M. M., Sweiss N., et al. Atypical ulcers: a stepwise approach for clinicians. Wounds. 2022; 34 (10): 236–244.

5. Isoherranen K., O’Brien J. J., Barker J., et al. Atypical wounds. Best clinical practice and challenges. J Wound Care. 2019; 28 (Sup- pl 6): 1–92.

6. Virkkala J., Polet S., Jokelainen J., et al. Clinical characteristics and comorbidities of the most common atypical wounds in Northern Finland in 1996-2019: A retrospective registry study. Health Sci Rep. 2022; 5 (5): e864.

7. Shanmugam V. K., Angra D., Rahimi H., McNish S. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord. 2017; 5 (2): 280–292.

8. Tang J. C., Vivas A., Rey A., et al. Atypical ulcers: wound biopsy results from a university wound pathology service. Ostomy Wound Manage. 2012; 58 (6): 20–22, 24, 26–29.

9. Janowska A., Dini V., Oranges T., et al. Atypical ulcers: diagnosis and management. Clin Interv Aging. 2019; 14: 2137–2143.

10. Kluger N., Koljonen V., Senet P. Martorell ulcer. Duodecim. 2013; 129 (10): 1031–1036.

11. Ansert E., Tickner A., Cohen D., et al. Understanding the zebras of wound care: an overview of atypical wounds. Wounds. 2022; 34 (5): 124–134.

12. Hamm R. L., Shah J. B. Atypical wounds. In: Text and Atlas of Wound Diagnosis and Treatment. Hamm R. L., ed. 2nd edn. McGraw-Hill Education; 2019.

13. Хэмм Р. Л. Раны. Диагностика и лечение. Атлас-справочник. Глава 8. Атипичные раны. М.: ГЭОТАР-Медиа, 2023.

14. Singer A. J., Tassiopoulos A., Kirsner R. S. Evaluation and management of lower-extremity ulcers. N Engl J Med. 2017; 377 (16): 1559–1567.

15. Stevenson P., Rodins K. Improving diagnostic accuracy of skin biopsies. Aust J Gen Pract. 2018; 47 (4): 216–220.

16. Elston D. M., Stratman E. J., Miller S. J. Skin biopsy: biopsy issues in specific diseases. J Am Acad Dermatol. 2016; 74 (1): 1–16.

17. Compton L. A., Murphy G. F., Lian C. G. Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology (Basel). 2015; 2 (1): 15–42.

18. Patel S., Maheshwari A., Chandra A. Biomarkers for wound healing and their evaluation. J Wound Care. 2016; 25 (1): 46–55.

19. Shavit E., Alavi A., Sibbald R.G. Vasculitis-what do we have to know? A review of literature. Int J Low Extrem Wounds. 2018; 17 (4): 218–226.

20. Riyaz N., Mary V., Sasidharanpillai S., et al. Pyodermagangrenosum: a clinico-epidemiologicalstudy. Indian J Dermatol Venereol Leprol. 2017; 83 (1): 33–39.

21. Stevens D. L, Bisno A. L., Chambers H. F., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59 (2): e10–e52.

22. Kain R. Histopathology. Methods Mol Biol. 2017; 1508: 185–193.

23. Alavi A., French L. E., Davis M.D., et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017; 18 (3): 355– 372.

24. Xu A., Balgobind A., Strunk A., et al. Prevalence estimates for pyoderma gangrenosum in the United States: an ageand sex-adjusted population analysis. J Am Academy Dermatol. 2020; 83 (2): 425–429.

25. Ahn C., Negus D., Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018; 14 (3): 225–233.

26. Braswell S. F., Kostopoulos T. C., Ortega-Loayza A.G. Pathophysiology of pyoderma gangrenosum (PG): An updated review. J Am Academy Dermatol. 2015; 73 (4): 691–698.

27. George C., Deroide F., Rustin M. Pyoderma gangrenosum — a guide to diagnosis and management. Clin Med (Lond). 2019; 19 (3): 224–228.

28. Maverakis E., Ma C., Shinkai K., et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018; 154 (4): 461–466.

29. Bennett M. L., Jackson J. M., Jorizzo J. L., et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000; 79 (1): 37–46.

30. Ahronowitz I., Harp J., Shinkai K. Etiology and management of pyoderma gangrenosum. Am J Clin Dermatol. 2012; 13 (3): 191– 211.

31. Ashchyan H. J., Butler D. C., Nelson C. A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018; 154 (4): 409–413.

32. Fraticelli P., Devis B., Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021; 16 (4): 831– 841.

33. Frumholtz L., Laurent‐Roussel S., Lipsker D., Terrier B. Cutaneous vasculitis: review on diagnosis and clinicopathologic correlations. Clin Rev Allergy Immunol. 2016; 61 (2): 181–193.

34. Roberto H., Brandt C., Arnone M., et al. Medium and large vessel vasculitis. An Bras Dermatol. 2009; 84 (1): 55–67.

35. Arora A., Wetter D. A., Gonzalez-Santiago T. M., et al. A population‐based study in Olmsted County, Minnesota. Mayo Clin Proc. 1996; 89: 1515–1524.

36. Watts R. A., Jolliffe V. A., Grattan C. E., et al. Cutaneous vasculitis in a defined population — clinical and epidemiological associations. J Rheumatol. 1998; 25 (5): 920–924.

37. Pannier F., Rabe E. Differential diagnosis of leg ulcers. Phlebology. 2013; 28 (Suppl 1): 55–60.

38. De Virgilio A., Greco A., Magliulo G., et al. Polyarteritis nodosa: a contemporary overview. Autoimmunity Rev. 2016; 15 (6): 564– 570.

39. Morgan A. J., Schwartz R. A. Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol. 2010; 49 (7): 750–756.

40. Martinez-Taboada V. M., Blanco R., Garcia-Fuentes M., Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997; 102 (2): 186–191.

41. Medhekar S. V., Vasani R. J., Kamath R. R. Leukocytoclastic vasculitis: a window to systemic churgstrauss syndrome. Indian J Dermatol. 2012; 57 (3): 215–218.

42. Yates M., Watts R. ANCA-associated vasculitis. Clin Med (London). 2017; 17 (1): 60–64.

43. Ekeigwe N. L., Adelowo O., Anaba E. L., Olaosebikan H. Eosinophilic granulomatosis with polyangiitis in a Nigerian woman. BMJ Case Rep. 2019; 12 (6): e228901.

44. Richetta A. G., Mattozzi C., Maiani E., et al. Skin ulcers in a patient afflicted with microscopic polyangiitis. Wounds. 2009; 21 (6): 141–143.

45. Becker R. C. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020; 50 (3): 499–511.

46. Kolivras A., Dehavay F., Delplace D., et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathologic findings. JAAD Case Rep. 2020; 6 (6): 489–492.

47. McGonagle D., Bridgewood C., Ramanan A. V., et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021; 3 (3): e224–e233.

48. Silva F., Pinto C., Barbosa A., et al. New insights in cryoglobulinemic vasculitis. J Autoimmun. 2019; 105: 102313.

49. Shanmugam V. K., DeMaria D. M., Attinger C. E. Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression. Clin Rheumatol. 2011; 30 (6): 849–853.

50. Oien R. F., Håkansson A., Hansen B. U. Leg ulcers in patients with rheumatoid arthritis — a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatol (Oxford). 2001; 40 (7): 816–820.

51. Hoffman M. D. Atypical ulcers. Dermatol Ther. 2013; 26 (3): 222–235.

52. Dabiri G., Falanga V. Connective tissue ulcers. J Tissue Viability. 2013; 22 (4): 92–102.

53. Shanmugam V. K., Price P., Attinger C. E., Steen V. D. Lower extremity ulcers in systemic sclerosis: features and response to therapy. Int J Rheumatol. 2010; 2010: 747946.

54. Yoo S. S., Mimouni D., Nikolskaia O. V., et al. Clinicopathologic features of ulcerativeatrophic sarcoidosis. Int J Dermatol. 2004; 43 (2): 108–112.

55. Hashemi D. A., Rosenbach M. Ulcerative sarcoidosis. JAMA Dermatology. 2019; 155 (2): 238–238.

56. Alhameedy M. M. Necrobiosis lipoidica: atypical presentation in a diabetic girl. Case Rep Dermatol. 2021; 13 (3): 547–552.

57. Marcoval J., Gómez-Armayones S., Valentí-Medina F., et al. Necrobiosis lipoidica: a descriptive study of 35 cases. Actas Dermosifiliogr. 2015; 106 (5): 402–407.

58. Nandeesh B., Tirumalae R. Direct immunofluorescence in cutaneous vasculitis: experience from a referral hospital in India. Indian J Dermatol. 2013; 58 (1): 22–25.

59. Sais G., Vidaller A., Jucglà A., et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998; 134 (3): 309–315.

60. Harvey N., Chan J., Wood B. Skin biopsy in the diagnosis of inflammatory skin disease. Aust Fam Physician. 2017; 46 (5): 283–288.

61. Carlson J. A. The histological assessment of cutaneous vasculitis. Histopathology. 2010; 56 (1): 3–23.

62. Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J. 2006; 82 (970): 483–488.

63. Luqmani R. A., Pathare S., Kwok-Fai T. L. How to diagnose and treat secondary forms of vasculitis. Best Pract Res Clin Rheumatol. 2005; 19 (2): 321–336.

64. Baigrie D., Goyal A., Crane J. S. Leukocytoclastic Vasculitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

65. Tilley C. P., Fu M. R., Van Cleeve J., et al. Symptoms of malignant fungating wounds and functional performance among patients with advanced cancer: an integrative review from 2000 to 2019. J Palliat Med. 2020; 23 (6): 848–862.

66. Trent J. T, Kirsner R. S. Wounds and malignancy. Adv Skin Wound Care. 2003; 16 (1): 31–34.

67. Altunay I., Çerman A. A., Sakiz D., Ates B. Marjolin’s ulcer presenting with intransit metastases: a case report and literature review. Ann Dermatol. 2015; 27 (4): 442– 445.

68. Miot H. A., Miot L. D., da Costa A. L., et al. Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J. 2006; 12 (2): 2.

69. Elkins-Williams S. T., Marston W. A., Hultman C. S. Management of the chronic burn wound. Clin Plast Surg. 2017; 44 (3): 679–687.

70. Martinez-Mera C., Fraga J., Capusan T. M., et al. Vasculopathies, cutaneous necrosis and emergency in dermatology. G Ital Dermatol Venereol. 2017; 152 (6): 615–637.

71. Siddiqi H. K., Libby P., Ridker P. M. COVID-19 — A vascular disease. Trends Cardiovasc Med. 2021; 31 (1): 1–5.

72. Jacobs-Kosmin D., DeHoratius R.J. Calciphylaxis: An important imitator of cutaneous vasculitis. Arthritis Care Res. 2007; 57 (3): 533–537.

73. Nigwekar S. U., Thadhani R., Brandenburg V. M. Calciphylaxis. N Engl J Med. 2018; 378 (18): 1704–1714.

74. Weenig R. H., Sewell L. D., Davis M. D., et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007; 56 (4): 569–579.

75. Varga Z., Flammer A. J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417–1418.

76. Mondal R., Lahiri D., Deb S., et al. COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection? J Thromb Thrombolysis. 2020; 50 (3): 567–579.

77. Magro C., Mulvey J. J., Berlin D., et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020; 220: 1–13.

78. Pickert A. An approach to vasculitis and vasculopathy. Cutis. 2012; 89 (5): E1– E3.

79. Nakashima M. O., Rogers H.J. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014; 49 (2): 85–94.

80. Babalola O. A., Ogunkeyede A., Odetunde A. B., et al. Haematological indices of sickle cell patients with chronic leg ulcers on compression therapy. Afr J Lab Med. 2020; 9 (1): 1037.

81. Sackey D., Dei-Adomakoh Y., Olayemi E. Enhanced hypercoagulability in sickle cell anaemia patients with chronic leg ulcers. Adv Hematol. 2020; 2020: 5157031.

82. Thornsberry L. A., LoSicco K. I., English J. C. The skin and hypercoagulable states. J Am Acad Dermatol. 2013; 69 (3): 450–462.

83. Rayner R, Carville K, Keaton J, et al. Leg ulcers: atypical presentations and associated comorbidities. Wound Pract Res. 2009; 17: 168–185.

84. Yotsu R. R., Suzuki K., Simmonds R. E., et al. Buruli ulcer: a review of the current knowledge. Curr Trop Med Rep. 2018; 5 (4): 247–256.

85. Marques S. A., Abbade L. P. F. Severe bacterial skin infections. An Bras Dermatol. 2020; 95 (4): 407–417.

86. Robson M. C., Heggers J. P. Bacterial quantification of open wounds. Mil Med. 1969; 134 (1): 19–24.

87. Bowler P. G. The 10(5) bacterial growth guideline: reassessing its clinical relevance in wound healing. Ostomy Wound Manage, 2003; 49 (1): 44–53.

88. Schultz G. S., Sibbald R. G., Falanga V., et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003; 11 (Suppl 1): S1–S28.

89. Edwards R., Harding K. G. Bacteria and wound healing. Curr Opin Infect Dis. 2004; 17 (2): 91–96.

90. Onesti M. G., Fioramonti P., Fino P., et al. Skin ulcer caused by venous extravasation of heroin. Int Wound J. 2014; 11 (4): 409– 411.

91. Coull A., Sharp A. Understanding leg ulceration associated with intravenous drug use. Nursing Times [online]. 2018; 114 (6): 31–34.

92. Reynolds F. H., 2nd, Hong M. W., Banks S. L. Extensive skin necrosis from suspected levamisole-contaminated cocaine. Cutis. 2015; 96 (3): E15–E17.

93. Best P. J., Daoud M. S., Pittelkow M. R., Petitt R. M. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 1998; 128 (1): 29–32.

94. Montefusco E., Alimena G., Gastaldi R., et al. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori. 1986; 72 (3): 317–21.

95. Souza C. F., Suarez O. M., Silva T. F., et al. Ulcerations due to methotrexate toxicity in a psoriasis patient. An Bras Dermatol. 2016; 91 (3): 375–377.

96. Alaya Z., Mokni S., Guerfala M., et al. Acute severe cutaneous methotrexate toxicity in a patient with rheumatoid arthritis: Report of a rare side effect. Egyptian Rheumatol. 2018; 40 (4): 281–284.

97. Shawwa K., Alraiyes A. H., Eisa N., Alraies M. C. Cocaine-induced leg ulceration. BMJ Case Reports. 2013; 2013: bcr2013200507.

98. Rodríguez Pichardo A., García Bravo B. Dermatitis artefacta: a review. Actas Dermosifiliogr. 2013; 104 (10): 854–866.

99. Amr A., Schmitt C., Kuipers T., et al. Identifying and managing patients with factitious wounds. Adv Skin Wound Care. 2017; 30: 1–7.

100. Michet C. J., Whitelock C., Siparsky N. It takes a village: the management of extreme sequelae of skin popping. Wounds. 2021; 33 (1): 9–19.

101. Laughter M. R., Florek A. G., Wisell J., Newman S. Dermatitis artefacta, a form of factitial disorder imposed on self, misdiagnosed as pyoderma gangrenosum for eight years. Cureus. 2020; 12 (7): e9054.

102. Saha A., Seth J., Gorai S., Bindal A. Dermatitis artefacta: a review of five cases: a diagnostic and therapeutic challenge. Indian J Dermatol. 2015; 60 (6): 61–65.

103. Manna B, Cooper JS. Radiation Therapy Induced Skin Ulcer. StatPearls Publishing. 2021.

104. Isbister G. K., Fan H. W. Spider bite. Lancet. 2011; 378 (9808): 2039–2047.

105. Blättler W., Zimmet S. E. Compression therapy in venous disease. Phlebology. 2008; 23 (5): 203–205.

106. Dini V., Romanelli M., Bertone M., et al. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds. 2007; 6 (2): 108–113.

107. González del Castillo J., Isernia V., Candel F. J., Martín-Sánchez F. J. Approach for initial treatment of skin and soft tissue infection. Clin Infect Dis. 2015; 60 (1): 169– 171.

108. Minniti C. P., Kato G. J. Critical reviews: how we treat sickle cell patients with leg ulcers. Am J Hematol. 2016; 91 (1): 22– 30.

109. Breuing K. H., Bayer L., Neuwalder J., Orgill D. P. Early experience using low-frequency ultrasound in chronic wounds. Ann Plast Surg. 2005; 55 (2): 183–187.

110. Hoppe I. C., Granick M. S. Debridement of chronic wounds: a qualitative systematic review of randomized controlled trials. Clin Plast Surg. 2012; 39 (3): 221– 228.

111. Madhok B. M., Vowden K., Vowden P. New techniques for wound debridement. Int Wound J. 2013; 10 (3): 247–251.

112. Wolcott R. D., Kennedy J. P, Dowd S. E. Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. J Wound Care. 2009; 18 (2): 54–56.

113. Boateng J., Catanzano O. Advanced therapeutic dressings for effective wound healing — A review. J Pharm Sci. 2015; 104 (11): 3653–3680.

114. Beiteke U., Bigge S., Reichenberger C., et al. Pain and pain management in dermatology. J Dtsch Dermatol Ges. 2015; 13 (10): 967–987.

115. Adderley U. J, Holt I. G. Topical agents and dressings for fungating wounds. Cochrane Database Syst Rev. 2014; 15 (5): CD003948.

116. Quattrone F., Dini V., Barbanera S., et al. Cutaneous ulcers associated with hydroxyurea therapy. J Tissue Viability. 2013; 22 (4): 112–121.

117. Sunderkötter C., Bonsmann G., Sindrilaru A., et al. Management of leukocytoclastic vasculitis. J Dermatolog Treat. 2005; 16 (4): 193– 206.

118. Linares M. A., Zakaria A., Nizran P. Skincancer. Prim Care. 2015; 42 (4): 645–659.

119. Hussein M. R. Skin metastasis: a pathologist’s perspective. J Cutan Pathol. 2010; 37 (9): e1–e20.

120. Driver V. R., Yao M., Miller C. J. Noncontact low-frequency ultrasound therapy in the treatment of chronic wounds: a meta-analysis. Wound Repair Regen. 2011; 19 (4): 475– 480.

121. Barnes R., Shahin Y., Gohil R., Chetter I. Electrical stimulation vs. standard care for chronic ulcer healing: a systematic review and meta-analysis of randomised controlled trials. Eur J Clin Invest. 2014; 44 (4): 429–440.

122. Dai T., Vrahas M. S., Murray C. K, Hamblin M. R. Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S. Review. Expert Rev Anti Infect Ther. 2012; 10 (2): 185–195.

123. Situm M., Kolić M. Atypical wounds: definition and classification. Acta Med Croatica. 2012; 66 (Suppl 1): 5–11.